Rocket Pharmaceuticals (RCKTW) Stock Price, News & Analysis

Company Overview

Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing gene therapies for rare and devastating diseases. The company’s programs are designed to address the underlying genetic causes of disease using technologies that include lentiviral and adeno-associated virus (AAV) vectors.

Rocket’s pipeline includes investigational therapies for hematologic, cardiovascular, and pediatric disorders. Its programs have included RP-L102 for Fanconi anemia, RP-L201 for leukocyte adhesion deficiency-I, RP-A501 for Danon disease, and RP-A601 for arrhythmogenic right ventricular cardiomyopathy associated with PKP2 mutations. These treatments are intended to provide functional copies of defective genes or otherwise restore the biological functions affected by inherited mutations.

Founded in 2015, Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey. The company conducts research and clinical-development activities in the United States and works with medical institutions and regulatory authorities to advance its therapies for patients with rare genetic diseases. Rocket Pharmaceuticals trades on Nasdaq under several securities, including the RCKTW warrant symbol.

Key Stats

• Today's Range: $0.0002 to $0.0077
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.04
• Volume: 2.78 million shs
• Average Volume: 65,738 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RCKTW
• CIK: 1281895
• Web: www.rocketpharma.com
• Phone: 16464409100
• Fax: N/A
• Employees: 240
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A